Daewoong-AZ Korea start to jointly sell hyperlipidemia treatment ‘Crestor’

Published: 2016-04-13 10:43:07

Updated: 2016-04-13 10:43:07

On the 11^th, Daewoong Pharmaceutical(CEO Jong-ok Lee) announced it made a strategic joint sales agreement of ‘Crestor(generic name: rosuvastatin),’ a hyperlipidemia treatment, with AstraZeneca(CEO Liz Chatwin), and started to sell it from the 1^st.

Under the joint sales agreement, Daewoong Pharm introduced Crestor of approximately KRW 80 billion sales(based on UBIST) in 2015, and plans to gener...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.